Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

LAIR-1 (CD305) Mouse, anti-Human, R718, Clone: DX26, BD OptiBuild™

Mouse Monoclonal Antibody

Supplier:  BD Biosciences 752267

Catalog No. BDB752267


Only null left
Add to Cart

Description

Description

The DX26 monoclonal antibody specifically binds to Leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1/ hLAIR1/Leukocyte-associated Ig-like receptor 1) that is encoded by LAIR1, and also known as, CD305. LAIR-1 is a ∼32 kDa type I transmembrane glycoprotein with a single immunoglobulin-like domain and a cytoplasmic tail containing two immune receptor tyrosine-based inhibitory (ITIM) motifs. LAIR-1 is expressed on T cells, B cells, NK cells, monocytes, and dendritic cells. LAIR-1 recruits SHP-1 and SHP-2 tyrosine phosphatases upon activation. Crosslinking of the LAIR-1 expressed on T cells or NK cells can result in strong inhibition of cell-mediated cytotoxicity. Although it is structurally related to human killer cell inhibitory receptors, LAIR-1 does not appear to recognize MHC class I molecules and thus represents a novel MHC class I-independent mechanism of NK cell regulation.

TRUSTED_SUSTAINABILITY
Specifications

Specifications

LAIR-1 (CD305)
Monoclonal
R718
50 μg
Primary
Refrigerate Upon Arrival
Flow Cytometry
DX26
Mouse
RUO
Human
Liquid
Product Suggestions

Product Suggestions

Videos
Safety and Handling

Safety and Handling

WARNING: Reproductive Harm - www.P65Warnings.ca.gov
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.